RxDoctor Payments Data

Neeraj Sriram, MD

Pain Medicine · Columbia, SCNPI 1467849943

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $8,310 of the $9,298 with a category attached, or 89.4%. 37 manufacturers reported payments, led by Medtronic at 25.4% of the total.

$9,298in general payments, 2019–2025

Across 284 payments — averaging $32.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Boston Scientific$2K
  • Collegium Pharmaceutical, Inc.$753
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$584
  • Abbott$296
  • Nalu Medical, Inc.$275
  • plus $3K from 31 others

What the payments were for

  • Travel & lodging$98811%
  • Food & beverage$8,31089%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,298 in reported general payments places this provider in the 80th percentile of 92 pain medicine providers in South Carolina.

See all pain medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$334,823
Medicare patients
392
Services billed
5,222

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate97$52,629
BelbucaBuprenorphine Hcl47$31,050
Buprenorphine129$28,112
Oxymorphone Hcl ErOxymorphone Hcl18$12,309
NucyntaTapentadol Hcl15$10,870
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen405$5,428
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen345$5,274
Gabapentin ErGabapentin13$5,210
Diclofenac Sodium64$2,587
Morphine Sulfate ErMorphine Sulfate77$2,218
Lidocaine30$2,210
Gabapentin177$2,018
Pregabalin130$1,960
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl21$1,727
Hydromorphone ErHydromorphone Hcl12$1,403

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca, Nucynta$753$94,549159 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 92 pain medicine providers in South Carolina.

Other pain medicine in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →